ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Report Urges NCI To Continue 5 A Day, Expand Funding For Communications.

February 9, 2001

UHC Expands Risk Models To Include 25 Cancer Variables

February 24, 2012

NCI Scientists Immunize A Healthy BMT Donor Against Myeloma

May 5, 1995

Cigarette Smoking increases Among Youth, Annual Report Finds

January 12, 1996

An Unlucky Streak? Doctors Analyze Errors As Another Cancer Center Offers Apology

June 30, 1995

RTOG: Hormone Therapy Increases Survival When Combined With Radiation Therapy

July 29, 2011